Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Other Events
Item 8.01 Other Events.
On December 4, 2016, Agios Pharmaceuticals, Inc. (the Company)
issued a press release announcing new clinical data from both the
Companys ongoing phase 2 DRIVE PK study evaluating AG-348 in
patients with pyruvate kinase deficiency and the Companys ongoing
phase 1 single ascending dose and multiple ascending dose study
of AG-519 in healthy volunteers.On December 5, 2016, the Company
issued a press release announcing new clinical data from the dose
escalation portion of the Companys ongoing phase 1 study
evaluating single agent AG-120 in patients with isocitrate
dehydrogenase-1 mutant positive advanced hematologic
malignancies.The Company presented these data at the 2016
American Society of Hematology Annual Meeting and Exposition
taking place December 3-6, 2016 in San Diego, California.
The full text of the press releases issued in connection with
these announcements are attached as Exhibit 99.1 and Exhibit 99.2
to this Current Report on Form 8-K and incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibits are included in this report:
|
ExhibitNo. |
Description |
|
| 99.1 |
Press release issued by Agios Pharmaceuticals, Inc. on December 4, 2016. |
|
| 99.2 |
Press release issued by Agios Pharmaceuticals, Inc. on December 5, 2016. |
About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Recent Trading Information
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closed its last trading session down -7.09 at 49.88 with 3,574,170 shares trading hands.